Virbagen Omega is a unique product containing a form of feline interferon. This is given by injection to treat certain viral infections and immune problems in both cats and dogs. The mechanism of action is not fully understood, but it has been found in clinical trials to be of benefit in such things as Parvo virus infection in dogs and Feline Leukamia virus infection. The precise treatment schedule has to be followed exactly to get the best results. For further information, see the datasheet below.
Virbagen Omega 10 MU for cats and dogs.
Vial containing lyophylisate.
Active substance 10 MU presentation:
Recombinant omega interferon of feline origin 10 MU*/vial.
*MU: Million units.
Sodium chloride, D-sorbitol, gelatin.
Vial containing solvent: isotonic sodium chloride solution 1ml.
Powder and solvent for suspension for injection.
Pharmaceutical group: ATC vet-Code: QL03 AB.
The exact mechanism of action of omega interferon is not perfectly known, but may involve the enhancement of the non-specific defence of the body, in particular in the dog against canine parvovirosis. Interferon does not act directly and specifically against the pathogenic virus, but exerts its effect by inhibition of the internal synthesis mechanisms of the infected cells. Omega interferon of feline origin, produced by genetic engineering, is a type 1 interferon related to alpha interferon. After injection it is quickly bound to specific receptors of a large variety of cells. It is mainly in cells infected by the virus that the mechanism of replication is stopped both by destruction of mRNA and by inactivation of translation proteins (2’ 5’ oligo-adenylate synthetase activation).
Target species: Dogs and Cats
For the reduction in mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.
Vaccination during and after Virbagen Omega treatment is contra-indicated until the dog appears to have recovered.
Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9
weeks. In a field study conducted, it was observed that there was :
- a reduction of clinical signs during the symptomatic phase (4 months)
- a reduction of mortality :
• in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.
• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.
In some cases during treatment the following transient clinical signs may be onserved:
Hyperthermia (3-6 hours after injection)
Soft faeces to mild diarrhoea, in cats only.
In addition, a slight decrease in white blood cells, platelets and red blood cells, and rise in the concentration of alanine aminotransferase may be observed. These parameters return to normal in the week following the last injection.
Transient fatigue during the treatment, in cats only.
Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.
Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of VIRBAGEN OMEGA. Fluid therapy and other supplementary supportive treatment are necessary to improve prognosis.
The product should be used with the accompanying solvent only.
The safety of Virbagen Omega has not been established during pregnancy and lactation.
The use of supplementary supportive treatments improves prognosis. No interaction has been observed during the treatment with VIRBAGEN OMEGA together with antibiotics, solution for rehydration, vitamins and non steroidal anti-inflammatory agents. However, as specific information on possible interactions of interferon with other products are missing, supplementary supportive treatments should be used cautiously and after a thorough risk/benefit analysis.
No information is available on the safety and efficacy from the concurrent use of this product with any other vaccine. For dogs, it is recommended that no vaccines should be administered until the animal appears to have recovered. Cat vaccination during and after VIRBAGEN OMEGA treatment is contraindicated as both FeLV and FIV infections are known to be immunosuppressive.
The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon.
The reconstituted product should be injected intravenously once daily for 3 consecutive days. The dose is 2.5 MU/kg bodyweight.
The reconstituted product should be injected subcutaneously once daily for 5 consecutive days. The dose is 1 MU/kg bodyweight. Three separate 5-day treatments must be performed at day 0, day 14 and day 60.
After a tenfold overdose in both dog and cat the following clinical signs have been observed :
• mild lethargy and drowsiness
• slight increase of body temperature.
• slight increase of respiratory rate
• slight sinus tachycardia.
These clinical signs disappear within 7 days without any particular treatment.
No information on the induction of long-term side effects is available in dog and cat, especially for autoimmune disorders. Such side effects have been described after multiple and long-term administration of type I interferon in man. The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.
Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.
In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.
Special precautions to be taken by the person administering the medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.
do not mix with any other vaccine/immunological product, except the solvent supplied for use with the product.
Store and transport at 4° C ± 2° C. Do not freeze. Store in the original carton.
Presentation of 10 MU per vial:
Box containing 5 vials (glass with stopper) of powder fraction and 5 vials (glass with stopper) with 1 ml of solvent.
Box containing 2 vials (glass with stopper) of powder fraction and 2 vials (glass with stopper) with 1 ml of solvent.
any unused product or waste materials should be disposed of according to local requirements.
FOR ANIMAL TREATMENT ONLY. KEEP OUT OF THE REACH OF CHILDREN
L.I.D. 1ere Avenue – 2065m
F-06516 CARROS – FRANCE
VIRBAGEN OMEGA (5 x 10MU) EU/2/01/030/002
VIRBAGEN OMEGA (2 x 10MU) EU/2/01/030/004
All prices include VAT where applicable.
Below are some recent questions we've received regarding Virbagen Omega for Dogs & Cats, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by: